Free Trial
Ends Tomorrow! Last Chance to Save $100 on MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Claim $100 Off
Claim MarketBeat All Access Sale Promotion

Mark Purcell Analyst Performance

Analyst at Morgan Stanley

Mark Purcell is a stock analyst at Morgan Stanley in the medical sector, covering 2 publicly traded companies. Over the past year, Mark Purcell has issued 2 stock ratings, including and buy recommendations. While full access to Mark Purcell's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Mark Purcell's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
2 Last 0 Years
Buy Recommendations
100.00% 2 Buy Ratings
Companies Covered
2 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%2 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NYSE
50.0% of companies on NYSE
1 company
NASDAQ
50.0% of companies on NASDAQ
1 company

Mark Purcell, an analyst at Morgan Stanley, currently covers 2 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
100.0%

Mark Purcell of Morgan Stanley specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
LARGE CAP PHARMA
2 companies
100.0%

Mark Purcell's Ratings History at Morgan Stanley

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Novartis AG stock logo
NVS
Novartis
3/26/2026Boost Price Target$150.32$170.00Overweight
Sanofi stock logo
SNY
Sanofi
9/8/2025Upgrade$46.50$58.00Overweight